Thiel-backed Azitra raises $3M for skin microbiome R&D; Crushed by clinical failure, Aviragen launches strategic review
→ Farmington, CT-based Azitra has raised close to $3 million in a Series A designed to fuel its research on microbiome therapies for the skin. Seeded by Peter Thiel’s Breakout Labs, the company identified a strain of bacteria that can be used in lotions to treat conditions like eczema and staph infections. Bios Partners led the round. “The current approach of only addressing a disease’s symptoms alone is ineffective, and the microbiome is a nascent area of groundbreaking science that has enormous potential,” said Azitra co-founder Travis Whitfill. “That’s why we were passionate about launching a commercial organization that harnesses the power of the skin’s own microbiome to develop a new kind of dermatology treatment. Such treatments are potentially safer, more highly targeted, and work better with fewer side effects than what’s currently available for often intractable conditions.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.